Predictive Oncology Inc.
POAI
$1.06
-$0.03-2.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 91.36% | -48.91% | -43.13% | 74.91% | -12.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.36% | -48.91% | -43.13% | 74.91% | -12.08% |
| Cost of Revenue | 20.18% | 101.12% | -4.26% | 56.04% | 57.63% |
| Gross Profit | 312.60% | -74.29% | -61.91% | 93.82% | -62.95% |
| SG&A Expenses | -21.15% | -25.77% | -19.67% | 24.67% | -33.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.16% | -22.13% | -19.09% | 25.68% | -30.25% |
| Operating Income | 29.74% | 15.52% | 15.99% | -22.27% | 31.75% |
| Income Before Tax | 29.79% | 16.92% | 18.91% | -23.29% | 62.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.79% | 16.92% | 18.91% | -23.29% | 62.20% |
| Earnings from Discontinued Operations | 85.78% | -95.45% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.57% | 2.17% | 18.91% | -23.29% | 56.10% |
| EBIT | 29.74% | 15.52% | 15.99% | -22.27% | 31.75% |
| EBITDA | 30.19% | 11.75% | 16.35% | -26.25% | 27.13% |
| EPS Basic | 62.01% | 38.35% | 30.53% | -20.42% | 57.47% |
| Normalized Basic EPS | 58.13% | 46.46% | 27.53% | -20.41% | 32.29% |
| EPS Diluted | 62.01% | 38.35% | 30.53% | -20.61% | 57.47% |
| Normalized Diluted EPS | 58.13% | 46.46% | 27.53% | -20.41% | 32.29% |
| Average Basic Shares Outstanding | 64.32% | 58.66% | 16.72% | 2.39% | 3.21% |
| Average Diluted Shares Outstanding | 64.32% | 58.66% | 16.72% | 2.39% | 3.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |